StiRx Inc. to Present Breakthrough Research on Gonorrhea Therapeutics at IPNC 2025

Cambridge, MA, April 2025 – StiRx Inc., a biotechnology company focused on advancing sexual health through innovative biologics, is proud to announce that new research from its pipeline will be presented at the upcoming 24th International Pathogenic Neisseria Conference (IPNC 2025), held from March 30 to April 4, 2025, in Florence, Italy.

Dr. Davinder Gill, CEO of StiRx, will present data on STX-426, a novel monoclonal antibody candidate engineered to target a key surface molecule of Neisseria gonorrhoeae. STX-426 has demonstrated potent bactericidal activity across multiple gonococcal strains, including drug-resistant variants. In preclinical studies, Fc-engineering further enhanced its functional activity and extended its plasma half-life, supporting the potential for durable protection and treatment with a single dose.

“Our team is deeply committed to tackling the urgent need for new approaches against gonorrhea, particularly in the face of rising antibiotic resistance,” said Dr. Gill. “We are excited to share data highlighting STX-426 as a promising long-acting therapeutic candidate aimed at empowering sexual health globally.”

The presentation will detail preclinical efficacy results in validated animal models and outline manufacturing and dose optimization efforts supporting future clinical development.

StiRx’s participation at IPNC 2025 underscores its leadership in advancing novel solutions against sexually transmitted infections, in alignment with the company’s mission to redefine sexual health for communities worldwide.

For more information, please visit www.stirx.bio.